KRAS and neoplasm: Induced expression of miR-23b-27b-24-1 increased drug sensitivity and reduced invasiveness of NSCLC cells by silencing gene members of the oncogenic NF-κB and KRAS pathways [95], also identifying a tumor suppressive role for this cluster.